BioVersys' AlpE regimen shows early antibacterial activity in Phase 2a tuberculosis trial
GSK•
GSK•BioVersys reported that AlpE combined with RZE showed antibacterial activity comparable to standard treatment in a Phase 2a trial, though the trial was not designed for formal comparisons. All tested regimens showed activity, and AlpE was generally well tolerated over 14 days.
BioVersys reported Phase 2a ENABLE results for AlpE in patients with newly diagnosed, drug-sensitive pulmonary tuberculosis. AlpE combined with RZE showed antibacterial activity comparable to standard treatment, but the trial was not designed for formal comparisons; all tested regimens showed activity, and AlpE was generally well tolerated over 14 days.
The results were presented at the Union World Conference on Lung Health in Rio de Janeiro, held November 17-20, 2026. A separate Phase 2b trial is evaluating AlpE-RZE during the first two months of treatment, while a Phase 2 meningitis program is advancing.